ASX Announcement

Melbourne, Australia, 23 November 2023

Results of 2023 Annual General Meeting

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX: EX1) is pleased to advise that shareholders of the Company passed all Resolutions at today's Annual General Meeting by way of poll.

In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed with in excess of 75% votes in favour of the resolution.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

By the Company Secretary – this announcement has been authorised for release by the Company Secretary, Mr David Franks, on behalf of the Board.

Company and Media Enquiries:

Join our mailing list to receive updates:
http://exo.ph/ExoMails
www.exopharm.com
P: +61 (0)3 9111 0026

Ian Dixon	Tel: +61 418 561 907
Managing Director	ian.dixon@exopharm.com

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in advanced manufacturing technologies for exosome-based medicines.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 23 March 2023.

Disclosure of Proxy Votes

Exopharm Limited

Annual General Meeting

Thursday, 23 November 2023

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	25,928,505	25,535,000 98.48%	323,505 1.25%	310,000	70,000 0.27%	26,987,500 98.82%	323,505 1.18%	310,000	-
2 Election of Clarke Barlow as Director	P	54,175,132	54,049,181 99.77%	55,951 0.10%	322,000	70,000 0.13%	55,501,681 99.90%	55,951 0.10%	322,000	Passed
3 Election of Mark Davies as Director	P	54,175,132	54,049,181 99.77%	55,951 0.10%	322,000	70,000 0.13%	55,501,681 99.90%	55,951 0.10%	322,000	Passed
4 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	54,187,132	54,061,012 99.77%	56,120 0.10%	310,000	70,000 0.13%	55,131,012 99.21%	438,620 0.79%	310,000	Passed
5 Approval of Issue of Director Options to Clarke Barlow, Director of the Company	P	54,187,132	51,850,580 95.69%	2,266,552 4.18%	310,000	70,000 0.13%	52,920,580 95.23%	2,649,052 4.77%	310,000	Passed
6 Approval of Issue of Director Options to Mark Davies, Director of the Company	P	54,187,132	51,850,580 95.69%	2,266,552 4.18%	310,000	70,000 0.13%	52,920,580 95.23%	2,649,052 4.77%	310,000	Passed